

# 1 Neutralization of SARS-CoV-2 variants by convalescent and 2 vaccinated serum

3

4 Timothy A. Bates<sup>1\*</sup>, Hans C. Leier<sup>1\*</sup>, Zoe L. Lyski<sup>1</sup>, Savannah K. McBride<sup>1</sup>, Felicity J.  
5 Coulter<sup>1</sup>, Jules B. Weinstein<sup>1</sup>, James R. Goodman<sup>2</sup>, Zhengchun Lu<sup>1</sup>, Sarah A. R. Siegel  
6 <sup>3</sup>, Peter Sullivan<sup>3</sup>, Matt Strnad<sup>3</sup>, Amanda E. Brunton<sup>3</sup>, David X. Lee<sup>1</sup>, Marcel E.  
7 Curlin<sup>4,#</sup>, William B. Messer<sup>1,3,4,#</sup>, Fikadu G. Tafesse<sup>1,#</sup>

8

## 9 Affiliations

10 <sup>1</sup>Department of Molecular Microbiology & Immunology, Oregon Health & Science  
11 University (OHSU), Portland, OR 97239, USA.

12 <sup>2</sup>Medical Scientist Training Program, Oregon Health & Science University (OHSU),  
13 Portland, OR 97239, USA

14 <sup>3</sup>OHSU-PSU School of Public Health, Program in Epidemiology, Portland, OR 97339,

15 <sup>4</sup>USA Department of Medicine, Division of Infectious Diseases, Oregon Health &  
16 Science University (OHSU), Portland, OR 97239, USA.

17 \*these authors contributed equally to this work.

18

19

20

21

22 #Correspondence to: Fikadu G. Tafesse [tafesse@ohsu.edu](mailto:tafesse@ohsu.edu), William B. Messer

23 [messer@ohsu.edu](mailto:messer@ohsu.edu), Marcel E. Curlin, [curlin@ohsu.edu](mailto:curlin@ohsu.edu)

24

25 **Abstract**

26 We tested human sera from large, demographically balanced cohorts of BNT162b2  
27 vaccine recipients (n=51) and COVID-19 patients (n=44) for neutralizing antibodies  
28 against SARS-CoV-2 variants B.1.1.7 and B.1.351. Although the effect is more  
29 pronounced in the vaccine cohort, both B.1.1.7 and B.1.351 show significantly reduced  
30 levels of neutralization by vaccinated and convalescent sera. Age is negatively  
31 correlated with neutralization in vaccinee, and levels of variant-specific RBD antibodies  
32 are proportional to neutralizing activities.

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47 **Main**

48 Since its emergence in Wuhan, China in late 2019, severe acute respiratory syndrome  
49 coronavirus 2 (SARS-CoV-2) has spread worldwide, causing widespread illness and  
50 mortality from coronavirus 2019 disease (COVID-19).<sup>1</sup> Continued SARS-CoV-2  
51 transmission has led to the emergence of variants of concern (VOCs) that show  
52 evidence of increased transmissibility or resistance to prior immunity.<sup>2</sup> By early 2021,  
53 three major VOCs were widely recognized: B.1.1.7, first identified in southeast England  
54 in November 2020<sup>3</sup>; B.1.351, identified in November in South Africa; and P.1, identified  
55 in December Brazil<sup>3,4</sup>. These VOCs were associated with increases in infections and  
56 hospitalizations in their countries of origin, and all have increased in frequency in other  
57 regions, suggesting a competitive fitness advantage over existing lineages.<sup>5</sup>

58        Though a relatively small number of nonsynonymous mutations and deletions  
59 distinguish VOCs from earlier lineages (Supplementary Table 1), many of these encode  
60 residues in the spike protein, which interacts with the SARS-CoV-2 cellular receptor,  
61 angiotensin-converting enzyme 2 (ACE2), via its receptor-binding domain (RBD)<sup>6,7</sup>.  
62 RBD mutations could potentially increase transmissibility by enhancing binding to  
63 ACE2, or promote immune escape by altering epitopes that are the primary target of  
64 potentially neutralizing antibodies.<sup>7</sup> In fact, the most prominent mutation that appeared  
65 early in the pandemic and rose to near-fixation in new strains was a substitution at spike  
66 residue position 614 (D614G) which positions the RBD in a more accessible  
67 configuration and confers greater infectivity but also greater susceptibility to neutralizing  
68 antibodies.<sup>8,9</sup>

69 In addition to sharing D614G and a N501Y substitution which is associated with  
70 greater ACE2 affinity,<sup>10</sup> VOCs have acquired other spike mutations, some of which are  
71 associated with resistance to antibody neutralization. These include E484K and  
72 K417N/T, both of which arose independently in the B.1.351 and P.1 lineages.<sup>11-13</sup>  
73 Epidemiological reports suggest that natural immunity to earlier SARS-CoV-2 lineages  
74 may confer limited protection from reinfection by B.1.351 or P.1<sup>3,14</sup>, and prior analyses  
75 using relatively small numbers of vaccinee sera against pseudotyped or chimeric  
76 viruses showed reduced neutralization of B.1.351 and P.1<sup>13,15</sup>. The purpose of this  
77 study was to use neutralization assays with clinical virus isolates to rigorously examine  
78 the potency of antibodies elicited by the BNT162b2 vaccine or natural infection against  
79 the broader antigenic RBD variability within the B.1.1.7 and B.1.351 variants.

80 The three COVID-19 vaccines authorized for emergency use by the U.S. Food  
81 and Drug Administration (BNT162b2 [Pfizer–BioNTech], mRNA-1273 [Moderna], and  
82 Ad26.COV2.S [Janssen]) elicit immunity using a spike protein antigen derived from  
83 early isolates such as USA\_WA1/2020 (WA1)<sup>16</sup>. RBD-binding antibody levels in adults  
84 who had received two doses of the BNT162b2 mRNA vaccine were determined by  
85 ELISA using recombinant RBD from WA1 (RBD-WA1) and RBDs with substitutions  
86 possessed by B.1.1.7 (N501Y) and B.1.351 (N501Y, E484K, K417N) (Table S1).  
87 Compared to that of RBD-WA1, vaccinated patient sera had a geometric mean 50%  
88 effective concentration (EC50) which was 1.3-fold lower (P=0.0411) for RBD-B.1.1.7  
89 and 1.4-fold lower (P=0.0047) for RBD-B.1.351 (Figure 1A). BNT162b2-elicited  
90 antibodies also displayed potent neutralizing activity against WA1 in a 50% focus  
91 reduction neutralization tests (FRNT50) (geometric mean titer (GMT) 1:393 +/- 2.5) but

92 decreased neutralization of B.1.1.7 (GMT 1:149 +/- 2.4) and B.1.351 (GMT 1:45 +/-  
93 2.3), representing 2.6-fold ( $P < 0.0001$ ) and 8.8-fold ( $P < 0.0001$ ) reductions, respectively  
94 (Figures 1B and S1). The positive correlation between serum EC50 and NT50 was  
95 consistent for each matched variant-RBD pair, indicating that variant-specific RBD-  
96 targeted antibody concentration is proportional to live virus neutralization capacity  
97 against each lineage (Figure 1C).

98         There was individual variation in the relative neutralization of the different  
99 variants. Neutralizing titers for WA1 and B.1.1.7 were highly correlated at the individual  
100 level (Figure 1D). In contrast, WA1 and B.1.351 FRNT50 titers correlated weakly at the  
101 individual level, with some individual's serum potentially neutralizing WA1 while having  
102 FRNT50 for B.1.351 below the assay limit of detection (1:20) (Figure 1E).

103         Older adults make up the most vulnerable population to COVID-19 and therefore  
104 have been prioritized for vaccination<sup>19</sup>. We found similar age-dependent decline in  
105 FRNT50 titers against each lineage in our study (Figures 1F-H). These differences were  
106 highly significant for all three variants between subgroups of younger (20-50 y.o. n=25)  
107 and older (>50 y.o. n=25) adults in our cohort (Figure 1I). There was no correlation  
108 between gender and neutralization titers after vaccination.

109         In contrast to the spike-specific antibody repertoire raised by BNT162b2  
110 vaccination, the antibody response to SARS-CoV-2 infection is more antigenically  
111 diverse<sup>7</sup>. Overall, RBD binding activities against all lineages were significantly lower in  
112 convalescent sera compared to vaccinee sera across all sample timepoints (1-301 days  
113 post-PCR positive) (Figures 1A and 2A and 2B). Moreover, there was no observable  
114 difference in convalescent serum EC50 between RBD-WA1, RBD-B.1.1.7, and RBD-

115 B.1.351 (Figure 2B). In convalescent sera, there was also no clear correlation between  
116 variant-specific RBD binding and neutralization (Figure 2C). To better capture the  
117 reduced antibody levels, we modified our ELISA protocol to reduce the limit of detection  
118 to 1:200 (compared with 1:1600 for vaccinee ELISAs). Differences in FRNT50 titer  
119 against WA1 and the VOCs were similarly reduced overall compared to vaccinee sera  
120 (WA1, GMTs 1:52.1 +/- 4.3; B.1.1.7, 1:36.8 +/- 3.0; B.1.351, 28.8 +/- 2.3) but showed  
121 substantially less variability with a 1.8-fold drop (CI) for B.1.351 and a 1.4-fold drop (CI)  
122 for B.1.1.7 relative to WA1 (Figures 2C and S2). Many convalescent sera fell below the  
123 FRNT limit of detection (Figures 2D-E): for WA1, 43% of convalescent cohort sera failed  
124 to neutralize  $\geq 50\%$  of input virus at the lowest dilution, and this proportion was even  
125 greater for the VOCs (B.1.1.7, 54%; B.1.351, 64%).

126 An important question surrounding the increasing evidence of reinfection in  
127 convalescent individuals by VOC is whether the severity of disease during the initial  
128 exposure is related to protection, or lack thereof, from reinfection<sup>3</sup>. Neutralizing titer in  
129 the convalescent cohort showed no significant correlation with the time between first  
130 confirmatory positive PCR result and sample collection, indicating relatively stable  
131 FRNT50 values over timescales up to 301 days (Figure 2F). Additionally, no correlation  
132 was found between neutralizing titer for any lineage and patient age, sex, or  
133 hospitalization for COVID-19 (Figures S3 and S4).

134 In this study we provide evidence of reduced antibody-mediated immunity to  
135 newly emerging SARS-CoV-2 variants B.1.1.7 and B.1.351 after immunization with the  
136 Pfizer-BioNTech COVID-19 vaccine or following natural infection. Our study involves a  
137 relatively large cohort, provides data well-balanced for gender and age distribution,

138 controls for time since vaccination, and directly compares early-type and two newly  
139 emerging SARS-CoV-2 variants of global concern. Critically, we use authentic clinical  
140 isolates that display the native antigenic landscape of the virus, an approach that  
141 provides the best possible examination of antibody activity against these viruses.

142         While it is likely that the resistance of some VOCs to neutralization is driven by  
143 accumulated mutations in the RBD and the rest of the spike protein, and there is  
144 evidence that high levels of RBD-binding antibodies is a meaningful correlate of  
145 protection from isogenic lineages<sup>7,17</sup>, other features of host immunity may contribute to  
146 protection. Specifically, the neutralization titers seen in our convalescent subjects, while  
147 lower overall, have a smaller gap in neutralizing activity between WA1 and VOCs than  
148 in BNT162b2 vaccinees. This difference between convalescents and vaccinees  
149 suggests that SARS-CoV-2 infection may elicit more broadly cross-reactive and  
150 potentially cross-neutralizing antibodies, even with reduced affinity for mutant RBDs.  
151 This notion has a strong foundation in coronavirus research, as there is substantial  
152 cross-reactivity of anti-SARS-CoV spike antibodies with SARS-CoV-2 spike<sup>18</sup>. Indeed,  
153 risk of reinfection by VOCs may be driven by generally low serological responses in  
154 most COVID-19 patients, rather than the presence of RBD mutations that allow immune  
155 escape. Other arms of the adaptive immune response that we did not explore here,  
156 such as T cell immunity, could also contribute to cross-lineage immunity<sup>19</sup>.

157         A particularly significant finding was the negative correlation between age and  
158 neutralizing antibody titer against VOCs in vaccinees, given that age is the predominant  
159 risk factor for severe COVID-19<sup>20</sup> and patients of advanced age stand to benefit the  
160 most from vaccination. Longitudinal studies of this and other cohorts could examine the

161 durability of vaccine-induced immune responses, and should be designed to resolve the  
162 nature of antibody responses induced by vaccination or natural infection that may  
163 correlate with broad cross-neutralization. This will be particularly important for  
164 developing vaccines that will be effective in vulnerable populations, including those of  
165 advanced age, against future SARS CoV-2 variants.

166

167 **Acknowledgements**

168 The authors thank the generous contribution of the many patients and vaccinees who  
169 participated in this study. In addition, we gratefully acknowledge the efforts of the entire  
170 OHSU Covid-19 serology study team.

171

172 **Funding**

173 This study was funded in part by an unrestricted grant from the M.J. Murdock Charitable  
174 Trust, by NIH training grant T32AI747225 on Interactions at the Microbe-Host Interface,  
175 and OHSU Innovative IDEA grant 1018784, and NIH R01AI145835.


176

177

<b>Table 1. Demographic characteristics of study participants</b>			
<b>Convalescent serum donors</b>			
<b>Characteristic</b>	<b>Hospitalized</b>		<b>Total (N=54)</b>
	<b>Yes (n=17)</b>	<b>No (n=37)</b>	
<b>Median age – yr (range)</b>	56 (22-88)	54 (1-80)	56 (1-88)
<b>Sex – no. (%)</b>			
Female	11 (35.4)	20 (64.5)	31 (57.4)
Male	6 (26.1)	17 (73.9)	23 (42.6)
<b>Symptomatic – no. (%)</b>			
No	3 (17.6)	1 (2.70)	4 (7.40)
Yes	14 (82.4)	36 (97.3)	50 (92.6)
<b>Admitted to ICU – no. (%)</b>			
Yes	5 (29.4)	NA	5 (9.25)
No	12 (70.6)	NA	12 (22.2)
<b>Median time between first positive COVID-19 PCR test and sample collection – days (range)</b>	21 (1-217)	197 (22-302)	188.5 (1-302)
<b>BNT162b2-vaccinated donors</b>			
<b>Characteristic</b>	<b>Total (N=51)</b>		
<b>Median age – yr (range)</b>	50 (21-82)		
<b>Sex – no. (%)</b>			
Female	28 (54.9)		
Male	23 (45.1)		
<b>Median time between vaccine doses – days (range)</b>	21 (20-22)		
<b>Median time between second dose and sample collection – days (range)</b>	14 (14-15)		

178

### BNT162b2 vaccine




179

180 **Figure 1. Serum antibody levels of BNT162b2 vaccine recipients and potency of sera to**  
 181 **neutralize SARS-CoV-2 variants.** A) Serum antibody levels (EC50) that recognize the spike  
 182 RBD of the wild type USA-WA1/2020 (WA1), B.1.1.7, and B.1.351 variants are shown. The  
 183 RBD-B.1.1.7 carries the N501Y mutation corresponding to the B.1.1.7 variant and the RBD-  
 184 B.1.135 has K417N, E484K, and N501Y mutations that are present in the B.1.351 variant. B)  
 185 Comparison of neutralization titers (FRNT50) between WA1, B.1.17 and B.1.351 for BNT162b2  
 186 vaccinee sera. C) Correlation of variant matched RBD-specific antibody levels and  
 187 neutralization titers (FRNT50) of the AW1 virus and the two variants. D, E) Correlations between  
 188 neutralization titers of the B.1.1.7 (D) and B.1.351 (E) variants with the WA1 virus. The dotted  
 189 diagonal lines indicate identical neutralization, and the solid diagonal black lines indicate 10-fold  
 190 differences in neutralization. F-H) Correlation between participant age and neutralization titer  
 191 against WA1 (F), B.1.1.7 (G), and B.1.351 (H). I) Effect of age range on the neutralization  
 192 potency among the BNT162b2 vaccine recipients.

193

194

### Natural infection



195

196

197 **Figure 2. Neutralization of SARS-CoV-2 variants by convalescent serum.**

198 A) Quantification of serum antibody levels (EC50) that recognize RBD protein corresponding to  
 199 the wild type (WA1), B.1.1.7, and B.1.351 variants. B) Comparison of neutralization titers between  
 200 WA1, B.1.17 and B.1.351 for convalescent sera. C) Relationship between convalescent antibody  
 201 levels and neutralization (FRNT50) of the different virus strains. D, E) Correlations between  
 202 convalescent serum neutralization titer of the B.1.1.7 (D) and B.1.351 (E) variants with the WA1  
 203 virus. The dotted diagonal lines indicate identical neutralization, and the solid diagonal black lines  
 204 indicate 10-fold differences in neutralization. F) Correlation of convalescent neutralization titers  
 205 with time after first positive PCR test in COVID-19 patients. There is no significant correlation  
 206 between days post positive PCR test and FRNT50 for the viral strains tested.

207

208

209

210

211

212

213

214

## 215 References

- 216
- 217 1 Noh, J. & Danuser, G. Estimation of the fraction of COVID-19 infected people in U.S.  
218 states and countries worldwide. *PLoS One* **16**, e0246772,  
219 doi:[10.1371/journal.pone.0246772](https://doi.org/10.1371/journal.pone.0246772) (2021).
- 220 2 Plante, J. A. *et al.* The Variant Gambit: COVID's Next Move. *Cell Host Microbe*,  
221 doi:<https://doi.org/10.1016/j.chom.2021.02.020> (2021).
- 222 3 Sabino, E. C. *et al.* Resurgence of COVID-19 in Manaus, Brazil, despite high  
223 seroprevalence. *Lancet* **397**, 452-455, doi:[10.1016/S0140-6736\(21\)00183-5](https://doi.org/10.1016/S0140-6736(21)00183-5) (2021).
- 224 4 Tegally, H. *et al.* Emergence and rapid spread of a new severe acute respiratory  
225 syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in  
226 South Africa. *medRxiv*, 2020.2012.2021.20248640, doi:[10.1101/2020.12.21.20248640](https://doi.org/10.1101/2020.12.21.20248640)  
227 (2020).
- 228 5 Walensky, R. P., Walke, H. T. & Fauci, A. S. SARS-CoV-2 Variants of Concern in the United  
229 States-Challenges and Opportunities. *JAMA*, doi:[10.1001/jama.2021.2294](https://doi.org/10.1001/jama.2021.2294) (2021).
- 230 6 Lan, J. *et al.* Structure of the SARS-CoV-2 spike receptor-binding domain bound to the  
231 ACE2 receptor. *Nature* **581**, 215-220, doi:[10.1038/s41586-020-2180-5](https://doi.org/10.1038/s41586-020-2180-5) (2020).
- 232 7 Robbiani, D. F. *et al.* Convergent antibody responses to SARS-CoV-2 in convalescent  
233 individuals. *Nature* **584**, 437-442, doi:[10.1038/s41586-020-2456-9](https://doi.org/10.1038/s41586-020-2456-9) (2020).
- 234 8 Gobeil, S. M. *et al.* D614G Mutation Alters SARS-CoV-2 Spike Conformation and  
235 Enhances Protease Cleavage at the S1/S2 Junction. *Cell Reports* **34**, 108630,  
236 doi:[10.1016/j.celrep.2020.108630](https://doi.org/10.1016/j.celrep.2020.108630) (2021).
- 237 9 Plante, J. A. *et al.* Spike mutation D614G alters SARS-CoV-2 fitness. *Nature*,  
238 doi:[10.1038/s41586-020-2895-3](https://doi.org/10.1038/s41586-020-2895-3) (2020).
- 239 10 Tian, F. *et al.* Mutation N501Y in RBD of Spike Protein Strengthens the Interaction  
240 between COVID-19 and its Receptor ACE2. *bioRxiv*, 2021.2002.2014.431117,  
241 doi:[10.1101/2021.02.14.431117](https://doi.org/10.1101/2021.02.14.431117) (2021).
- 242 11 Greaney, A. J. *et al.* Comprehensive mapping of mutations in the SARS-CoV-2 receptor-  
243 binding domain that affect recognition by polyclonal human plasma antibodies. *Cell Host*  
244 *Microbe*, doi:[10.1016/j.chom.2021.02.003](https://doi.org/10.1016/j.chom.2021.02.003) (2021).
- 245 12 Weisblum, Y. *et al.* Escape from neutralizing antibodies by SARS-CoV-2 spike protein  
246 variants. *eLife* **9**, e61312, doi:[10.7554/eLife.61312](https://doi.org/10.7554/eLife.61312) (2020).
- 247 13 Garcia-Beltran, W. F. *et al.* Circulating SARS-CoV-2 variants escape neutralization by  
248 vaccine-induced humoral immunity. *medRxiv*, 2021.2002.2014.21251704,  
249 doi:[10.1101/2021.02.14.21251704](https://doi.org/10.1101/2021.02.14.21251704) (2021).
- 250 14 Novavax. (2021).
- 251 15 Xie, X. *et al.* Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y  
252 variants by BNT162b2 vaccine-elicited sera. *Nature Medicine*, doi:[10.1038/s41591-021-](https://doi.org/10.1038/s41591-021-01270-4)  
253 [01270-4](https://doi.org/10.1038/s41591-021-01270-4) (2021).
- 254 16 Forni, G. & Mantovani, A. COVID-19 vaccines: where we stand and challenges ahead.  
255 *Cell Death & Differentiation* **28**, 626-639, doi:[10.1038/s41418-020-00720-9](https://doi.org/10.1038/s41418-020-00720-9) (2021).
- 256 17 Barnes, C. O. *et al.* SARS-CoV-2 neutralizing antibody structures inform therapeutic  
257 strategies. *Nature* **588**, 682-687, doi:[10.1038/s41586-020-2852-1](https://doi.org/10.1038/s41586-020-2852-1) (2020).

- 258 18 Bates, T. A. *et al.* Cross-reactivity of SARS-CoV structural protein antibodies against  
259 SARS-CoV-2. *Cell Reports*, 108737, doi:10.1016/j.celrep.2021.108737 (2021).
- 260 19 Zuo, J. *et al.* Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months  
261 following primary infection. *Nature Immunology*, doi:10.1038/s41590-021-00902-8  
262 (2021).
- 263 20 Rosenthal, N., Cao, Z., Gundrum, J., Sianis, J. & Safo, S. Risk Factors Associated With In-  
264 Hospital Mortality in a US National Sample of Patients With COVID-19. *JAMA Netw Open*  
265 **3**, e2029058, doi:10.1001/jamanetworkopen.2020.29058 (2020).  
266  
267

## 268 **SUPPLEMENTARY INFORMATION**

269

## 270 **MATERIALS AND METHODS**

271

272 This study was conducted in accordance with the Oregon Health & Science University

273 Institutional Review Board (IRB#00022511 & #21230).

274

### 275 **Serum collection (Vaccinated cohort - IRB#00022511)**

276 Subjects were enrolled at Oregon Health & Science University immediately after receiving their

277 first dose of the Pfizer-BioNTech COVID-19 vaccine. After obtaining informed consent, 4-6 mL

278 of whole blood were collected (BD Vacutainer® Plus Plastic Serum Tubes) and centrifuged for

279 10 minutes at 1000 x g. A second blood sample was obtained 14-15 days after subjects received

280 their second dose of the Pfizer-BioNTech COVID-19 vaccine. Samples were stored at -20°C

281 until sera were collected for neutralization assay. A subset of serological samples (n=51) was

282 randomly selected while maintaining equal gender representation, balanced age distribution, time

283 between vaccination doses equal to 21 days +/- 1 day, and time from boost to blood sampling

284 equal to 14 days +/- 1 day. Randomization was performed using R version 4.0.3 in RStudio

285 version 1.2.5001.

286

### 287 **Serum collection (Natural infection cohort - IRB#21230)**

288 Subjects with confirmed COVID-19 infection were part of a larger cohort of COVID-19

289 individuals at the Oregon Health & Science University. After obtaining informed consent, 10mL

290 of whole blood was collected for serum (BD Vacutainer® Red Top Serum Tubes), and 40mL of  
291 whole blood were collected for PBMCs and plasma (BD Vacutainer® Lavender Top EDTA  
292 Tubes). Serum tubes were centrifuged for 10 minutes at 1000 x g. Samples were heat-inactivated  
293 for 30 minutes at 56°C and stored at -20°C until needed. A subset of serological samples (n=54)  
294 from individuals with time post infection (determined by date of first positive PCR) ranging from  
295 1 day – 10 months, a spectrum of disease severity scores and clinical disease ranging from  
296 asymptomatic to severe (hospitalized in the ICU) were chosen for this analysis.

297

### 298 **Cell culture**

299 Vero E6 monkey kidney epithelial cells (CRL-1586) were obtained from the ATCC. Unless  
300 otherwise stated, cells were maintained at all times in standard tissue culture-treated vessels in  
301 complete media (DMEM, 10% FBS, 1% nonessential amino acids, 1% penicillin-streptomycin)  
302 at 37°C and 5% CO<sub>2</sub>.

303

### 304 **SARS-CoV-2 growth and titration**

305 SARS-CoV-2 isolates USA/CA\_CDC\_5574/2020 [lineage B.1.1.7] (NR-54011), hCoV-19/South  
306 Africa/KRISP-K005325/2020 [lineage B.1.351] (NR-54009), and USA-WA1/2020<sup>1</sup> [lineage A]  
307 (NR-52281) were obtained through BEI Resources. Sub-confluent monolayers of Vero E6 cells  
308 in 75 cm<sup>2</sup> flasks were inoculated with the p0 isolates and grown for 72 h, at which time  
309 significant cytopathic effect was observed for all strains. Culture supernatants were removed,  
310 centrifuged 10 min at 1,000 x g, and stored in aliquots at -80°C. To determine titer, confluent  
311 monolayers of Vero E6 cells in 96-well plates were inoculated with tenfold serial dilutions of  
312 SARS-CoV-2 prepared in dilution media (Opti-MEM, 2% FBS) for 1 h at 37°C, then covered

313 with overlay media (Opti-MEM, 2% FBS, 1% methylcellulose) and cultured an additional 24 h.  
314 Overlay media was then removed, and plates were fixed for 1 h in 4% paraformaldehyde in PBS.  
315 Foci were developed as described.<sup>2</sup> In brief, cells were permeabilized for 30 minutes in perm  
316 buffer (0.1% BSA, 0.1% Saponin in PBS) and incubated with 1:5,000 anti-SARS-CoV-2 alpaca  
317 serum for 2 hours at room temperature. Plates were washed three times with wash buffer (0.01%  
318 Tween-20 in PBS), then incubated with 1:20,000 anti-alpaca-HRP (Novus #NB7242) for 2 hours  
319 at room temperature. Plates were again washed three times with wash buffer and 30 $\mu$ L of KPL  
320 TrueBlue substrate (Seracare #5510-0030) added to each well. Plates were incubated at room  
321 temperature for 20 minutes and imaged with a CTL Immunospot Analyzer, then foci were  
322 counted using CTL ImmunoSpot (7.0.26.0) Professional DC.

323

324 Additional SARS-CoV-2 isolates were propagated and titrated during the development of this  
325 assay. They included the three previously described clinical isolates: USA/CA\_CDC\_5574/2020  
326 [lineage B.1.1.7] (NR-54011), hCoV-19/South Africa/KRISP-K005325/2020 [lineage B.1.351]  
327 (NR-54009), and USA-WA1/2020<sup>1</sup> [lineage A] (NR-52281) as well as two additional clinical  
328 isolates: hCoV-19/South Africa/KRISP-EC-K005321/2020 [lineage B.1.351] (NR-54008) and  
329 hCoV-19/England/204820464/2020 (NR-54000). Substantial differences were noted in the focus  
330 phenotypes of these strains (Fig. S5).

331

### 332 **SARS-CoV-2 FRNT**

333 Serial dilutions of patient sera and virus neutralization were carried out in duplicate, using  
334 separately prepared dilutions, in a 96-well plate format. Briefly, each sample was added in  
335 duplicate 1:10 to dilution media, and 4 four-fold serial dilutions were made spanning a range

336 from 1:10 to 1:2560. An equal volume of dilution media containing 50 FFU of SARS-CoV-2  
337 was added to each well (final dilutions of sera, 1:20 – 1:5120) and incubated 1 h at 37°C. The  
338 virus-sera mixtures were then added to monolayers of Vero E6 in corresponding 96-well plates,  
339 incubated 1 h at 37°C, and covered with overlay media. Fixation, foci development, and  
340 counting were carried out as described above. Focus counts were used to calculate percent  
341 neutralization by dividing by the average of positive control wells without patient serum  
342 treatment.

343

#### 344 **Production of variant RBDs**

345 Site-directed mutagenesis was used to introduce mutations into WT RBD. Purified SARS-CoV-2  
346 WA1, B.1.1.7, and B.1.351 RBD protein was prepared as previously described.<sup>2</sup> Briefly,  
347 sequence confirmed recombinant RBD lentiviruses was produced and used to generate stable  
348 HEK293F cells, which were allowed to grow for 3 days before collecting the cell media and  
349 purifying by Ni-NTA chromatography. The purified protein was buffer exchanged into PBS and  
350 concentrated by 10 kDa cutoff column and purity was assessed by SDS-PAGE.

351

#### 352 **ELISA**

353 ELISAs were performed in biological duplicate 96-well plates (Nunc™ MaxiSorp™ #423501).  
354 Plates were coated 100 uL/well with purified wild-type SARS-CoV-2 RBD, RBD-501, or RBD-  
355 3M constructs at 1 ug/mL in PBS and incubated overnight at 4°C with rocking. Plates were then  
356 washed three times with wash buffer (0.05% Tween-20 in PBS) and blocked with 150 uL/well  
357 blocking buffer (5% nonfat dry milk powder and 0.05% Tween-20 in PBS) at RT for 1 hour with  
358 rocking. Infected and vaccinated patient sera were initially diluted in Opti-MEM in the 96-well

359 plate format used above. For the ELISA, diluted vaccinated and infected patient sera was further  
360 diluted in blocking buffer on the plate (4×4-fold dilutions from 1:200 for infected patients; 4 2-  
361 fold dilutions from 1:1,600 for vaccinated patients). After incubating at RT for 1 hour with  
362 rocking, plates were washed three times. The secondary antibody Goat anti-Human IgG, IgM,  
363 IgA (H+L) (Invitrogen, #A18847) was diluted in blocking buffer (1:10,000) and applied to the  
364 plates 100 uL/well. Plates were protected from light and incubated at RT for 1 hour with rocking,  
365 then washed three times prior to the addition of the peroxidase activity detector 3,3',5,5'-  
366 tetramethylbenzidine (TMB, Thermo Scientific Pierce 1-Step Ultra TMB ELISA Substrate  
367 #34029). The reaction was stopped after 5 minutes using an equivalent volume of 1 M H<sub>2</sub>SO<sub>4</sub>;  
368 optical density (OD) was measured at 450 nm using a CLARIOstar plate reader. OD<sub>450</sub> readings  
369 were normalized by subtracting the average of negative control wells and finally dividing by the  
370 average maximum signal (95<sup>th</sup> percentile) for each unique coating protein in each experiment.

371

### 372 **FRNT50 and EC50 calculation**

373 Percent neutralization values for FRNT50 or normalized OD<sub>450</sub> values for EC<sub>50</sub> were compiled  
374 and analyzed using python (v3.7.6) with numpy (v1.18.1), scipy (v1.4.1), and pandas (v1.0.1)  
375 data analysis libraries. Data from biological replicates was combined and fit with a three-  
376 parameter logistic model. For FRNT50's, values were simultaneously calculated for individual  
377 biological replicates and patients for whom individual replicate FRNT50 values differed by more  
378 than 4-fold were excluded from further analysis. Final FRNT50 values below the limit of  
379 detection (1:20) were set to 1:19. Final EC<sub>50</sub> values below the limit of detection (1:1600 for  
380 vaccine cohort, 1:200 for natural infection cohort) were set to 1:1599 for the vaccine cohort and

381 1:199 for the natural infection cohort. EC50 and FRNT50 curves were plotted using python with  
382 the Matplotlib (v3.1.3) data visualization library.

383

#### 384 **Statistical analysis**

385 Aggregated EC50 and FRNT50 values were analyzed in Graphpad Prism (v9.0.2). EC50 and  
386 FRNT50 data were log transformed and one-way ANOVA using the Šidák multiple comparison  
387 correction was used for columnated data while two-way ANOVA using the Šidák multiple  
388 comparison correction was used for grouped data. The reported statistical methods are indicated  
389 in the relevant figure legends. Comparison of fold reduction and 95% confidence intervals for  
390 EC50 and FRNT50 were generated using one-way ANOVA. Patient samples with missing data  
391 points or demographic information were excluded from individual analyses which utilized those  
392 values.

393

394


395

396 **Table S1.** List of mutations in B.1.1.7 and B.1.351 SARS-CoV-2 clinical isolates\*

Lineage	GISAIID Clade	GISAIID ID	Spike mutations (RBD highlighted)	Non-Spike mutations
<b>B.1.1.7</b>	GR	EPI_ISL_683466	H69del, V70del, Y145del, <b>N501Y</b> , A570D, D614G, P681H, T716I, S982A, D1118H	N D3L, N G204R, N R203K, N S235F, NS8 Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP3 A1305V, NSP3 I1412T, NSP3 T183I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 K460R, NSP14 E347G
<b>B.1.351</b>	GH	EPI_ISL_678570	D80A, D215G, L242del, A243del, L244del, <b>K417N</b> , <b>E484K</b> , <b>N501Y</b> , D614G, A701V	E P71L, N T205I, NS3 Q57H, NS3 S171L, NSP2 T85I, NSP3 K837N, NSP5 K90R, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L


397 \*Obtained from BEI Resources

398



399

400 **Figure S1.** Neutralization curves of serum (n = 51) against the different strains of SARS-CoV-2  
401 are shown. Serum was collected two weeks after the second dose of the BNT162b2  
402 vaccine. Error bars represent SEM of biological replicates.



403

404 **Figure S2.** Neutralization plots of convalescent sera (n = 44) against the different strains of

405 SARS-CoV-2 are shown. Error bars represent SEM of biological replicates.


406

407

408

409

### BNT162b2 vaccine- sex correlations



410

411 **Figure S3.** Comparison of vaccine sera neutralization titers (NT50) of the different SARS-CoV-


412 2 strains with sex. There is no significant correlation between gender and NT50 among vaccinees.

413 Statistical comparison was performed using a two-way ANOVA with the Šidák multiple

414 comparison correction. There is no significance correlation between vaccine serum neutralization


415 titers with sex.

### Natural infection correlates



416

417 **Figure S4.** Correlates of selected demographic and clinical factors with neutralization in the  
418 COVID-19 convalescent cohort. A-C) Correlation of convalescent neutralization titers with sex  
419 (A), hospitalization versus ambulatory care (B), and age of COVID-19 patients (C). Statistical  
420 comparisons were performed using a two-way ANOVA with the Šidák multiple comparison  
421 correction. There is no significance correlation between convalescent neutralization titers and  
422 sex, hospitalization, age or days after a positive COVID-19 test.



423

424 **Figure S5.** Focus assay well images showing an example of the utilized titration curves for the  
425 clinical isolates tested during for assay development (A). Increased resolution of wells with  
426 individual foci (B). Average focus size for each isolate (C). Individual focus sizes were measured  
427 manually using ImageJ using the images indicated in (B). The average size indicates the mean  
428 number of pixels across all foci in each image, excluding those contacting the edge of the well.

429

430 **References**

431

432 1. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United  
433 States. *New England Journal of Medicine* 2020;382(10):929-936. DOI:  
434 [10.1056/nejmoa2001191](https://doi.org/10.1056/nejmoa2001191).

435 2. Bates TA, Weinstein JB, Farley S, Leier HC, Messer WB, Tafesse FG. Cross-reactivity of  
436 SARS-CoV structural protein antibodies against SARS-CoV-2. *Cell Reports*  
437 2021:108737. DOI: [10.1016/j.celrep.2021.108737](https://doi.org/10.1016/j.celrep.2021.108737).

438

439

440